Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — William Blair Growth Conference (June 2026)
16 slides from Telix Pharmaceuticals's conference presentation, Jun 2, 2026
Slide 1: William Blair Growth Conference
William Blair Growth Conference Dr. Chris Behrenbruch Managing Director and Group CEO Dr. David N. Cade Chief Medical Officer June 2, 2026
Slide 2: Forward looking statement
Forward looking statement This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on
Slide 3: Five pillars defining our competitive leadership in radiopharma
Five pillars defining our competitive leadership in radiopharma Integrated Theranostic Approach See It. Treat It. High value R&D platform for Precision Specialist Vertically therapeutics new molecular Medicine commercial integrated pipeline entities portfolio organization manufacturing and supply ch
Slide 4: Two FDA approved PSMA imaging agents on the market expanding patient reach
Two FDA approved PSMA imaging agents on the market expanding patient reach • Launched in 22 countries1 • Next-gen PSMA-PET imaging • 17 countries1 in Europe agent in the U.S. with longer shelf-life • NDA under review by NMPA in China2 • Reimbursement secured4 • Registration enabling study in • Incre
Slide 5: Accelerating revenue growth to record levels
Accelerating revenue growth to record levels 16% QoQ growth in Q1, 2026 Precision Medicine sales 191US$M 25% 186 16% 181 171 161 161 154 155 4% 1% 150 3% 151 8% 141 139 131 Q4 Q4, 202424 Q1Q1, 25 2025 Q2, 25 Q2 2025 Q3Q3, 25 2025 Q4Q4, 25 2025 Q1, 26 Q1 2026 5
Slide 6: Two first-in-class imaging agents for glioma and renal masses potentially first to market
Two first-in-class imaging agents for glioma and renal masses potentially first to market1,2 3 3 • PDUFA date: Sep 11, 2026 • Completed two type A meetings with the • Pixlumi ®3 MAA accepted in Europe FDA. BLA resubmission in progress • Included in National Comprehensive Cancer • Inclusion in the In
Slide 7: Precision Medicine portfolio near-term growth between 20% and 40% CAGR
Precision Medicine portfolio near-term growth between 20% and 40% CAGR Precision Medicine business Growth sensitivity analysis (USD) $5.2B Growth potential $3.6B $2.4B ~$1B 2027 2028 2029 2030 2031 (2026) 20% CAGR 30% CAGR 40% CAGR Not intended as a forecast or guidance, subject to change due to mar
Slide 8: A science-driven, isotope and targeting agent agnostic approach to R&D
A science-driven, isotope and targeting agent agnostic approach to R&D Collaboration with Regeneron In-house R&D capabilities Targeting agents Small Nanobody scFv Diabody Minibody scFv-Fc IgG△CH2 IgG molecule/ peptide 1.6 kDa3 15 28 55 80 100 130 150 Radioisotopes Four initial therapeutic programs β
Slide 9: Pipeline: Late-stage and "next-generation" assets
Pipeline: Late-stage and “next-generation” assets 9
Slide 10: Select therapeutics pipeline programs
Select therapeutics pipeline programs
Slide 11: A multi-product prostate cancer therapy portfolio
A multi-product prostate cancer therapy portfolio Aligned to disease state, patient needs and clinical opportunity Hormone-sensitive Castration-resistant Metastatic hormone-sensitive Metastatic castration-resistant Palliative TLX090-Tx TLX592-Tx Phase 3 TLX591-Tx TLX597-Tx in PSMA+ mCRPC OPTIMAL-E p
Slide 12: TLX591-Tx: A novel first-in-class rADC in 1L/2L mCRPC
TLX591-Tx: A novel first-in-class rADC in 1L/2L mCRPC Phase 3 trial: Part 2 is enrolling patients outside U.S.1 Differentiation Clinical data Phase 3 program • High internalization, retention and In combination with SoC (abiraterone, • Safety and tolerability profile reported selectivity for tumors
Slide 13: TLX597-Tx: next-gen small molecule candidate for mHSPC
TLX597-Tx: next-gen small molecule candidate for mHSPC Phase 2a trial: OPTIMAL-E study initiating Differentiation Clinical data Phase 2 programs • Dosimetry suggests best-in-class Proof of concept data from Ph2 IIT OPTIMAL-PSMA3 (n = 120), mCRPC small molecule profile highlighting2: Evaluating a hig
Slide 14: TLX101-Tx: First-in-class candidate for GBM
TLX101-Tx: First-in-class candidate for GBM, the most aggressive and common primary brain tumor Differentiation Positive Phase 2 data Late- and early-stage trials • Intravenous delivery with ability to Median OS of 32.2 months from cross blood brain barrier1 initial diagnosis and 12.4 months from •
Slide 15: TLX250-Tx: First-in-class rADC targeting ccRCC
TLX250-Tx: First-in-class rADC targeting ccRCC Differentiation Phase 1 & Phase 2 data Phase 2/3 trial • Novel mechanism of action, positioned Promising signals of efficacy in Phase 1 and LUTEON, Pivotal monotherapy trial to be first CAIX targeting rADC to the a Phase 2 RCC monotherapy studies with a
Slide 16: Contact:
Contact: Annie Kasparian Investor Relations & Corporate Communications June 2, 2026
Telix Pharmaceuticals — William Blair Growth Conference (June 2026) on 6ix